Loading
Multiparametric prostate MRI combines three scan sequences, scored 1 to 5 under PI-RADS, and is done before a first biopsy in men with a raised PSA. Needles go to suspicious areas and men with a negative scan can often avoid biopsy altogether, but about one in ten clinically significant cancers is missed.
Multiparametric prostate MRI combines T2-weighted, diffusion-weighted and dynamic contrast sequences, scored 1 to 5 under PI-RADS v2.1 for the likelihood of clinically significant cancer. It is performed before a first biopsy in men with a raised PSA, so needles can be targeted to suspicious lesions and men with a negative scan can often avoid biopsy. PRECISION (2018) showed MRI-targeted biopsy detected more clinically significant cancer (38% versus 26%) and less insignificant cancer than systematic biopsy, with 28% of men avoiding biopsy; it is now guideline standard before first biopsy. Reader variability remains a limitation and about 10% of significant cancers are missed, so relying on a negative MRI alone in higher-risk men is still debated. AI reading (PI-CAI challenge) matches radiologists. In short, an MRI first finds the cancers that matter and spares many men a biopsy.
T2-weighted, diffusion-weighted, and dynamic contrast sequences scored 1-5 for likelihood of significant cancer.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"Multiparametric prostate MRI" OR ABSTRACT:"Multiparametric prostate MRI" OR TITLE:"PI-RADS" OR ABSTRACT:"PI-RADS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Multiparametric prostate MRI (PI-RADS), not a curated reading list.
Shares PSA density, PSA kinetics: PSA doubling time and PSA density, Ductal adenocarcinoma of the prostate, TNM staging for prostate cancer, and what changed in the 9th edition.
Shares PSA density, PSA and MRI-first prostate cancer screening, Localised prostate cancer, very low and low risk, Active surveillance.
Shares PSA kinetics: PSA doubling time and PSA density, Ductal adenocarcinoma of the prostate, TNM staging for prostate cancer, and what changed in the 9th edition, PSA and MRI-first prostate cancer screening.
Shares PRECISION, Localised prostate cancer, very low and low risk, Active surveillance, Prostate cancer.
Shares GÖTEBORG-2 (MRI-based prostate cancer screening), Localised prostate cancer, very low and low risk, Prostate cancer.
Shares PSA and MRI-first prostate cancer screening, Localised prostate cancer, very low and low risk, Active surveillance, Overdiagnosis and false alarms.
Shares PRECISION, Localised prostate cancer, very low and low risk, Prostate cancer.
Shares PSA and MRI-first prostate cancer screening, Localised prostate cancer, very low and low risk, MRI, Prostate cancer.
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Preprocessing from the PI-CAI challenge for AI detection of clinically significant prostate cancer on biparametric MRI.